An interventional efficacy and safety Phase 3 double-blind 2-arm study to investigate IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis.

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of candidemia and/or invasive candidiasis - see link to cliinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- require hemodialysis, peritoneal dialysis, or hemofiltration - received > 2 days (> 48 hours) equivalent of prior systemic antifungal treatment at approved doses and frequency to treat the current episode of candidemia and/or invasive candidiasis - women who are pregnant or breastfeeding - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:
Drug: Caspofungin, Drug: Fluconazole, Drug: Fosmanogepix, Drug: Fosmanogepix, Drug: Placebo, Drug: Placebo, Drug: Placebo, Drug: Placebo
Conditions:
Infectious Diseases
Keywords:
Candidemia, fungal infection

More Information

Description: The purpose of this study is to compare effects of the study drug fosmanogepix with already-approved drugs caspofungin and fluconazole to find out if fosmanogepix is safe and effective in treating patients with candidemia and/or invasive candidiasis.
Study Contact: Tyler Pham - pham0225@umn.edu
Principal Investigator: Jo-Anne Young, MD
Phase: PHASE3
IRB Number: STUDY00023155